Literature DB >> 20808220

Blunt cerebrovascular trauma.

Clay Cothren Burlew1, Walter L Biffl.   

Abstract

PURPOSE OF REVIEW: Blunt cerebrovascular injuries (BCVI) are a rare but potentially devastating injury with stroke rates up to 50%. Over the past decade, the recognition and subsequent management of these injuries has undergone a marked evolution. This review will focus on the rationale for BCVI screening, imaging options, and treatment modalities. RECENT
FINDINGS: There are no prospective randomized controlled trials evaluating the management of BCVI. Available studies support screening a high-risk patient population based upon injury mechanism and constellation of associated injuries using multidetector-row (16-slice or greater) computed tomographic angiography (CTA). Although the ideal regimen of antithrombotic therapy has yet to be determined, treatment with either anticoagulation or antiplatelet agents has been shown to reduce BCVI-related stroke rate.
SUMMARY: Cerebrovascular injuries (CVI) are now diagnosed in approximately 1% of blunt trauma patients. The recognition of a clinically silent period allows for injury screening based upon mechanism of trauma and the patient's injury pattern. Following identification of injuries in asymptomatic patients, prompt initiation of antithrombotic therapy reduces the incidence of stroke.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20808220     DOI: 10.1097/MCC.0b013e32833ee8b4

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  9 in total

Review 1.  Blunt vertebral vascular injury in trauma patients: ATLS® recommendations and review of current evidence.

Authors:  Roozbeh Shafafy; Sukrit Suresh; John O Afolayan; Alexander R Vaccaro; Jaykar R Panchmatia
Journal:  J Spine Surg       Date:  2017-06

2.  A cohort study of blunt cerebrovascular injury screening in children: Are they just little adults?

Authors:  Mackenzie R Cook; Cordelie E Witt; Robert H Bonow; Eileen M Bulger; Ken F Linnau; Saman Arbabi; Bryce R H Robinson; Joseph Cuschieri
Journal:  J Trauma Acute Care Surg       Date:  2018-01       Impact factor: 3.313

3.  Screening via CT angiogram after traumatic cervical spine fractures: narrowing imaging to improve cost effectiveness. Experience of a Level I trauma center.

Authors:  Megan M Lockwood; Gabriel A Smith; Joseph Tanenbaum; Daniel Lubelski; Andreea Seicean; Jonathan Pace; Edward C Benzel; Thomas E Mroz; Michael P Steinmetz
Journal:  J Neurosurg Spine       Date:  2015-11-27

4.  Factors associated with blunt cerebrovascular injury in patients with cervical spine injury.

Authors:  Hiroyuki Nakajima; Manabu Nemoto; Tetsuya Torio; Ririko Takeda; Hidetoshi Ooigawa; Ryuichiro Araki; Hiroki Kurita
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-12-27       Impact factor: 1.742

Review 5.  Contemporary Strategies in the Management of Civilian Neck Zone II Vascular Trauma.

Authors:  Georgios Karaolanis; Konstantinos Maltezos; Chris Bakoyiannis; Sotiris Georgopoulos
Journal:  Front Surg       Date:  2017-09-29

Review 6.  Current Concepts in Imaging Diagnosis and Screening of Blunt Cerebrovascular Injuries.

Authors:  Tiffany Y So; Apurva Sawhney; Lei Wang; Yi Xiang J Wang
Journal:  Tomography       Date:  2022-02-07

7.  Stroke Secondary to Traumatic Carotid Artery Injury - A Case Report.

Authors:  Zoltán Bajkó; Smaranda Maier; Anca Moţăţăianu; Rodica Bălaşa; Smaranda Vasiu; Adina Stoian; Sebastian Andone
Journal:  J Crit Care Med (Targu Mures)       Date:  2018-02-09

8.  The limitations of using risk factors to screen for blunt cerebrovascular injuries: the harder you look, the more you find.

Authors:  Lewis E Jacobson; Mary Ziemba-Davis; Argenis J Herrera
Journal:  World J Emerg Surg       Date:  2015-09-26       Impact factor: 5.469

9.  Direct penetrating and indirect neck trauma as a cause of internal carotid artery thrombosis and secondary ischemic stroke.

Authors:  Karol Karnecki; Zbigniew Jankowski; Michał Kaliszan
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.